Omnicell (NASDAQ:OMCL) Share Price Breaks Above 200 Day Moving Average – Should You Sell?

Omnicell, Inc. (NASDAQ:OMCL) shares crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $38.91 and traded as high as $39.63. Omnicell shares last traded at $39.41, with a volume of 850,494 shares changing hands.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Wells Fargo & Company lowered their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. KeyCorp restated an “overweight” rating on shares of Omnicell in a research note on Monday, August 24th. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 price target (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Weiss Ratings upgraded shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. Finally, Zacks Research raised shares of Omnicell from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Omnicell has an average rating of “Moderate Buy” and an average target price of $57.86.

Omnicell Stock Performance

The company has a quick ratio of 1.45, a current ratio of 1.65 and a debt-to-equity ratio of 0.13. The stock has a 50-day moving average of $34.76 and a 200 day moving average of $38.91. The stock has a market cap of $1.79 billion, a PE ratio of 41.05, a P/E/G ratio of 0.97 and a beta of 0.88.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, October 29th. The company reported $0.58 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.16. The firm had revenue of $307.85 million for the quarter, compared to analysts’ expectations of $304.44 million. Omnicell had a return on equity of 5.69% and a net margin of 3.59%. The firm’s quarterly revenue was down .9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.51 earnings per share. Equities analysts predict that Omnicell, Inc. will post 1.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Omnicell

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Versant Capital Management Inc grew its stake in Omnicell by 38.7% during the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after purchasing an additional 294 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Omnicell by 21.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,613 shares of the company’s stock valued at $89,000 after buying an additional 469 shares during the last quarter. Nykredit A S purchased a new stake in shares of Omnicell in the 2nd quarter valued at about $26,000. Fulcrum Asset Management LLP boosted its holdings in shares of Omnicell by 2,536.4% in the third quarter. Fulcrum Asset Management LLP now owns 1,160 shares of the company’s stock valued at $40,000 after acquiring an additional 1,116 shares during the period. Finally, Crossmark Global Holdings Inc. grew its position in Omnicell by 17.4% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 9,121 shares of the company’s stock worth $311,000 after purchasing an additional 1,352 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.